Global Autotransfusion Devices and Consumables Market - 2024-2031
Global Autotransfusion Devices and Consumables Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031
Autotransfusion devices are medical devices used to collect and reinfuse a patient's own blood during and after surgery, reducing the need for allogeneic (donor) blood transfusions. These devices are crucial in managing blood loss and minimising the risk of transfusion-related complications. Autotransfusion systems are used in various surgeries with high blood loss, such as cardiac, orthopaedic, trauma, vascular, obstetric, and transplant procedures. They consistently provide high-quality washed red blood cells with excellent heparin and protein removal.
Market Dynamics: Drivers & RestraintsRise in the number of surgical procedures
These surgeries, characterized by substantial blood loss, benefit immensely from autotransfusion technology, which offers clinical and economic advantages by enhancing patient safety, reducing transfusion-related risks, and improving overall surgical outcomes. As these surgical procedures continue to rise globally, the reliance on and adoption of autotransfusion devices is expected to increase correspondingly.
For instance, according to the American Academy of Orthopaedic Surgeons (AAOS) and the Agency for Healthcare Research and Quality (AHRQ), an estimated 700,000 knee replacement and around 450,000 hip replacement procedures are performed in the U.S. each year. Besides, according to an article published by the University of Alabama in 2021, it was reported that 320,000 Coronary Artery Bypass Grafting procedures were performed in the U.S. in 2020. This, combined with the increasing awareness of intraoperative & post-operative blood salvage, is anticipated to offer substantial opportunity for the growth of the global market.
Rise in shift towards minimally invasive surgeries
The trend of patients shifting from invasive surgeries to minimally invasive ones is expected to increase due to factors like reduced hospital stays, cost, faster recovery, and superior patient comfort. Hence, this shift is expected to decrease the need for blood conservation or allogeneic transfer.
Segment AnalysisThe global autotransfusion devices and consumables market is segmented based on product type, usage, application, end-user and region.
The blood processing and collection devices from the product type segment accounted for approximately 41.3% of the autotransfusion devices and consumables market share
The blood processing and collection devices from the product type segment accounted for approximately 41.3%. Blood processing and collection devices play a crucial role in the autotransfusion devices market. These devices are essential components of autotransfusion systems, enabling the collection, processing, and reinfusion of a patient's own blood during surgical procedures. By utilizing autotransfusion devices, blood shed during surgery can be collected, processed, and filtered to remove impurities before being reinfused back into the patient, reducing the need for allogeneic (donor) blood transfusions.
Geographical AnalysisNorth America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like mainly due to the presence of key players in the country, rising healthcare expenses, and the increasing number of surgeries. Moreover, FDA approvals, novel product launches and increasing awareness of autotransfusion devices due to the lack of allogeneic blood in the region are some of the factors increasing the autotransfusion devices market size during the forecast period.
For instance, in February 2024, ProCell Surgical received CE-marked approval for its Sponge Blood Recovery Unit, allowing it to enter the European Union market. The certification indicates that ProCell’s product complies with the EU’s Medical Devices Regulation (EU) 2017/745. The company’s patented technology modernises the process of surgical sponge-blood recovery, enhancing intraoperative autotransfusion (IAT) systems in hospitals.
Moreover, in March 2023, Haemonetics Corporation, a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on the next-generation software for the Cell Saver Elite Autotransfusion System.
Covid 19 Impact Analysis
The COVID-19 pandemic significantly impacted the autotransfusion devices market growth, causing a significant decline in revenue due to a decrease in surgical procedures. These devices are primarily used in surgeries with high blood loss, such as orthopaedic and cardiac surgeries. The demand for autologous blood transfusion devices also decreased.
The American Medical Association reported a 48% reduction in total surgical procedures in the U.S., but after restrictions normalized, the volume of procedures returned to normal levels. The recent COVID-19 variant outbreak in the U.K. and India further restricted surgical procedures, increasing the burden on affected countries. Healthcare facilities are adapting to the situation.
Market SegmentationBy Product Type
• Blood Processing and Collection Devices
• Vacuum Pump and Accessories
• Consumables
• Others
By Usage
• Perioperative Usage
• Post-Operative Usage
By Application
• Cardiovascular Surgery
• Orthopedic Surgery
• Trauma Surgery
• Others
By End-User
• Hospitals
• Ambulatory Surgical Centers
• Others
By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa
Competitive LandscapeThe major global players in the market include Medtronic Plc, LivaNova Plc, Haemonetics Corporation, Fresenius SE & Co. KGaA, Terumo Corporation, Zimmer Biomet Holdings Inc, Braile Biomédica, Redax, Beijing ZKSK Technology, Advancis Surgical among others.
Key Developments In September 2022, i-SEP received CE-marking and initiated marketing of its autotransfusion medical device, Same by i-SEP. It is one of the intraoperative autotransfusion technology capable of preserving platelets in addition to the patient’s red blood cells.
In June 2022, Haemonetics launched a manufacturing centre of Excellence in Clinton, Pennsylvania for the development of auto-transfusion systems. The custom-built facility is expected to expand the product offerings of the company.
Why Purchase the Report??
• To visualize the global autotransfusion devices and consumables market segmentation based on product type, usage, application, end user and region as well as understand key commercial assets and players.
• identify commercial opportunities by analyzing trends and co-development.
• excel data sheet with numerous data points of the autotransfusion devices and consumables market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global autotransfusion devices and consumables market report would provide approximately 64 tables, 61 figures and 186 pages.
Target Audience 2023• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies